Documento de la Sociedad Española de Reumatología sobre la osteoporosis posmenopáusica

Revista Espanola de Reumatologia

Volumn 28, Issue 3, 2001, Pages 148-153

  Alonso Ruiz, A ^b   Beltran Audera Ch ^b   Blanch I Rubio J ^a   Caamano Freire M ^b   Carbonell Abello J ^b   Garcia Vadillo J A ^b   Guanabens Gay N ^b   Nolla Sole J M ^b   Rodriguez Arboleya L ^b   Rodriguez Perez M ^b   Roig Escofet, D ^b   Salas Heredia, E ^b   Torrijos Eslava, A ^b  

^a HOSPITAL DEL MAR   (Spain)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0000935278     PISSN: 03044815     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535-41.
2. Consensus development conference: diagnosis, prophylaxis and treatment of osteoporosis. Am J Med 1993; 94: 646-50.
3. 3 and calcium to prevent hip fractures in elderly women. N Engl J Med 1992; 327: 1637-42.
4. Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med 2000; 109: 267-76.
5. Eddy DM, Jonhston CC, Cummings SR, Dawson-Hughes B, Lindsay R, Melton LJ III et al. Osteoporosis: Review of evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Osteoporos Int 1998; 8 (Supl 4): S1-S88.
6. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 1999: 282: 637-45.
7. Harris ST, Watts NB, Genant HK. McKeever CD, Hangartner T, Keller M et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344-52.
8. Kiel DP, Felson DT, Anderson JJ, Wilson PW, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. N Engl J Med 1987; 317: 1169-74.
9. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992; 117: 1-9.
10. NIH Consensus Conference: Optimal calcium intake. NIH Consensus development panel on optimal calcium intake. JAMA 1994; 272: 1942-8.
11. Watts NB. Clinical utility of biochemical markers of bone remodelling. Clin Chem 1999; 45: 1359-68.
12. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990; 323: 73-9.
13. WHO Study Group on assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843, Ginebra: WHO, 1994.